Published in Cell Oncol (Dordr) on June 07, 2011
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer (2014) 0.96
Early detection biomarkers for ovarian cancer. J Oncol (2012) 0.95
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res (2013) 0.91
Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways. J Oncol (2012) 0.88
Targeting folate receptor alpha for cancer treatment. Oncotarget (2016) 0.84
Vintafolide: a novel targeted therapy for the treatment of folate receptor expressing tumors. Ther Adv Med Oncol (2015) 0.82
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancer. Int J Cancer (2015) 0.81
Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget (2016) 0.77
Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer. PLoS One (2015) 0.75
Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer. Int J Womens Health (2014) 0.75
Precision targeted therapy of ovarian cancer. J Control Release (2016) 0.75
Potent Therapeutic Activity Against Peritoneal Dissemination and Malignant Ascites by the Novel Anti-Folate Receptor Alpha Antibody KHK2805. Transl Oncol (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet (2000) 5.33
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res (2007) 3.03
Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.63
Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A (1991) 2.16
Overexpression of folate binding protein in ovarian cancers. Int J Cancer (1997) 2.13
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun (2007) 1.82
Folate receptors. Annu Rev Nutr (1996) 1.82
Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug Chem (2002) 1.48
Expression of folate receptor type alpha in relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix. Cancer Epidemiol Biomarkers Prev (1999) 1.40
Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res (2009) 1.26
Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther (2010) 1.21
Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med (2003) 1.14
Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med (1998) 1.14
Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer (2006) 1.01
A step further in understanding the biology of the folate receptor in ovarian carcinoma. Gynecol Oncol (2003) 0.92
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem (2005) 4.65
In vitro and in vivo two-photon luminescence imaging of single gold nanorods. Proc Natl Acad Sci U S A (2005) 3.66
In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry. Proc Natl Acad Sci U S A (2007) 2.70
Folate-mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev (2002) 2.56
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci (2005) 2.46
Assembly and regulation of a glycolytic enzyme complex on the human erythrocyte membrane. Proc Natl Acad Sci U S A (2005) 2.44
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Uptake and trafficking of fluorescent conjugates of folic acid in intact kidney determined using intravital two-photon microscopy. Am J Physiol Cell Physiol (2004) 2.16
Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med (2009) 2.12
Obtaining adequate surgical margins in breast-conserving therapy for patients with early-stage breast cancer: current modalities and future directions. Ann Surg Oncol (2009) 2.02
Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol (2008) 2.01
Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo forster resonance energy transfer imaging. Langmuir (2008) 1.88
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
Receptor conversion in distant breast cancer metastases. Breast Cancer Res (2010) 1.85
Folate-targeted therapies for cancer. J Med Chem (2010) 1.73
Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res (2008) 1.70
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Folate receptor overexpression is associated with poor outcome in breast cancer. Int J Cancer (2007) 1.65
Evaluation of disulfide reduction during receptor-mediated endocytosis by using FRET imaging. Proc Natl Acad Sci U S A (2006) 1.65
Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother (2002) 1.63
Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med (2011) 1.62
Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Deliv Rev (2004) 1.59
Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev (2004) 1.58
Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev (2008) 1.58
Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer (2006) 1.55
A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages. Blood (2008) 1.49
Adducin forms a bridge between the erythrocyte membrane and its cytoskeleton and regulates membrane cohesion. Blood (2009) 1.42
A role for the proton-coupled folate transporter (PCFT-SLC46A1) in folate receptor-mediated endocytosis. J Biol Chem (2008) 1.41
Intraoperative multispectral fluorescence imaging for the detection of the sentinel lymph node in cervical cancer: a novel concept. Mol Imaging Biol (2011) 1.41
Approach and management of primary ectopic breast carcinoma in the axilla: where are we? A comprehensive historical literature review. J Plast Reconstr Aesthet Surg (2010) 1.40
Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol (2003) 1.36
Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm (2009) 1.36
High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS One (2012) 1.36
Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol (2004) 1.35
Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer (2008) 1.34
Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (99m)Tc-radioimaging agents. Mol Pharm (2009) 1.31
Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol (2003) 1.31
Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol (2004) 1.31
Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration. Neurobiol Aging (2008) 1.30
Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum (2002) 1.30
Regulation of membrane-cytoskeletal interactions by tyrosine phosphorylation of erythrocyte band 3. Blood (2011) 1.29
Adequate debridement and drainage of the mediastinum using open thoracotomy or video-assisted thoracoscopic surgery for Boerhaave's syndrome. Surg Endosc (2011) 1.28
Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett (2004) 1.28
Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clin Cancer Res (2007) 1.27
TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol (2009) 1.26
Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer (2009) 1.26
Erythrocyte detergent-resistant membrane proteins: their characterization and selective uptake during malarial infection. Blood (2003) 1.26
Headpiece domain of dematin is required for the stability of the erythrocyte membrane. Proc Natl Acad Sci U S A (2002) 1.26
Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt (2003) 1.26
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol (2006) 1.24
Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol (2005) 1.24
Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int J Cancer (2006) 1.23
Modulation of red cell glycolysis: interactions between vertebrate hemoglobins and cytoplasmic domains of band 3 red cell membrane proteins. Am J Physiol Regul Integr Comp Physiol (2004) 1.23
Mapping of glycolytic enzyme-binding sites on human erythrocyte band 3. Biochem J (2006) 1.23
Identification of a critical ankyrin-binding loop on the cytoplasmic domain of erythrocyte membrane band 3 by crystal structure analysis and site-directed mutagenesis. J Biol Chem (2002) 1.23
Characterization of glycolytic enzyme interactions with murine erythrocyte membranes in wild-type and membrane protein knockout mice. Blood (2008) 1.23
Multispectral optoacoustic tomography of matrix metalloproteinase activity in vulnerable human carotid plaques. Mol Imaging Biol (2012) 1.22
An osmotically induced cytosolic Ca2+ transient activates calcineurin signaling to mediate ion homeostasis and salt tolerance of Saccharomyces cerevisiae. J Biol Chem (2002) 1.22
Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases. Cancer (2012) 1.18
Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folate-linked therapeutic agents. Arch Pathol Lab Med (2012) 1.17
Osteopontin regulates actin cytoskeleton and contributes to cell proliferation in primary erythroblasts. J Biol Chem (2008) 1.16
The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res (2003) 1.15
Immunohistochemical expression of folate receptor alpha in colorectal carcinoma: patterns and biological significance. Hum Pathol (2008) 1.14
Lower rate of major bile duct injury and increased intraoperative management of common bile duct stones after implementation of routine intraoperative cholangiography. J Am Coll Surg (2011) 1.13
Involvement of the TGF-beta and beta-catenin pathways in pelvic lymph node metastasis in early-stage cervical cancer. Clin Cancer Res (2011) 1.13
Characterization of the deoxyhemoglobin binding site on human erythrocyte band 3: implications for O2 regulation of erythrocyte properties. Blood (2007) 1.13
Synthesis and activity of a folate peptide camptothecin prodrug. Bioorg Med Chem Lett (2006) 1.12
PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des (2004) 1.12
Imaging of the diffusion of single band 3 molecules on normal and mutant erythrocytes. Blood (2009) 1.12
Distinct roles of phenol-soluble modulins in spreading of Staphylococcus aureus on wet surfaces. Appl Environ Microbiol (2012) 1.11
Role of band 3 in regulating metabolic flux of red blood cells. Proc Natl Acad Sci U S A (2009) 1.10
Profiling studies in ovarian cancer: a review. Oncologist (2007) 1.09
Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer (2006) 1.08
Current concepts and future perspectives on surgical optical imaging in cancer. J Biomed Opt (2011) 1.08
Intraoperative assessment of biliary anatomy for prevention of bile duct injury: a review of current and future patient safety interventions. Surg Endosc (2011) 1.08
Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer (2012) 1.07
Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma. Nat Commun (2013) 1.06
CADM1 and MAL promoter methylation levels in hrHPV-positive cervical scrapes increase proportional to degree and duration of underlying cervical disease. Int J Cancer (2013) 1.06
Peroxiredoxin-2 expression is increased in beta-thalassemic mouse red cells but is displaced from the membrane as a marker of oxidative stress. Free Radic Biol Med (2010) 1.06
In vivo evaluation of bacterial infection involving morphologically different surgical meshes. Ann Surg (2010) 1.05
LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy. J Cell Sci (2012) 1.05
Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther (2006) 1.05
Cholesterol level regulates endosome motility via Rab proteins. Biophys J (2007) 1.04
Detecting cervical cancer by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res (2004) 1.04
Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against hapten-decorated cancer cells. Int J Cancer (2005) 1.04
Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res (2009) 1.03
89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med (2013) 1.03